Sign In
Buy RDY
$13.02
-0.0100 (-0.0767%)
At Close: Jun 03, 2026
Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Call Transcript
04:31pm, Friday, 28'th Oct 2022
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2023 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Aga
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
01:40pm, Friday, 07'th Oct 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
11:17am, Friday, 07'th Oct 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
08:30am, Monday, 12'th Sep 2022 Zacks Investment Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
04:13pm, Friday, 09'th Sep 2022 Zacks Investment Research
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
01:33pm, Friday, 09'th Sep 2022
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
02:20pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Plaintiff in first Zantac lawsuit set for trial drops case
02:54pm, Wednesday, 17'th Aug 2022
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
01:45pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth
01:13am, Sunday, 31'st Jul 2022
Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treat
Dr. Reddy's Laboratories Limited's (RDY) CEO Erez Israeli on Q1 2023 Results - Earnings Call Transcript
01:03am, Sunday, 31'st Jul 2022
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2023 Earnings Conference Call July 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Parag Agar
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
08:28pm, Friday, 29'th Jul 2022 Zacks Investment Research
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
06:39pm, Friday, 29'th Jul 2022
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
01:50pm, Friday, 20'th May 2022 Zacks Investment Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
